FORE Biotherapeutics
Agent37Agent Readiness: 37/100. Below median. Measured by StartupHub.ai. Median 41.Trust84Data Trust: 84/100. Top 25%. Measured by StartupHub.ai. Median 61.Precision oncology company developing cancer therapies guided by proprietary functional genomics.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
FORE Biotherapeutics is a precision oncology company dedicated to pioneering the development of novel cancer therapies. Their approach is deeply rooted in science and innovation, utilizing proprietary functional genomics to guide their therapeutic development. Their vision is to compassionately contribute to solving cancer.
Similar companies
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Shares Healthcare, Drug Development
Develops a computational model of the human body for drug discovery and development.
Shares Healthcare, Drug Discovery
AI-powered spatial biology platform for precision medicine and drug development.
Shares Healthcare, Oncology
Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.
Shares Healthcare, Genomics
Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.
Shares Healthcare, Genomics
AI-powered platform for profiling cancer biomarkers from digitized biopsy images.
Shares Healthcare, Genomics
Key facts
- Website
- fore.bio
- Headquarters
- Philadelphia, United States
- Founded
- 2011
- Employees
- 56
- Total funding
- $232M (Series D-2 Extension)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 7 Jul 2026 | Series D-2 Extension | $67M | SR One, Medicxi | |
| 23 Aug 2023 | Series D | $75M | SR One, Medicxi | |
| 1 Mar 2021 | Series A | $17M | Novartis Venture Fund, Pfizer Ventures | |
| 21 Sept 2020 | Series C | $57M | $75M | |
| 31 Mar 2018 | Undisclosed round | $6M | ||
| 30 Nov 2015 | Undisclosed round | $10M |
Tech stack
Detected on fore.bio, last scanned 3 Nov 2026. Run your own scan
- Email provider
- Microsoft 365
FORE Biotherapeutics scores 52. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is FORE Biotherapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for FORE Biotherapeutics is 84 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has FORE Biotherapeutics raised?
FORE Biotherapeutics has raised a total of $232M in funding. The most recent round on record is Series D-2 Extension.
How many employees does FORE Biotherapeutics have?
FORE Biotherapeutics has approximately 56 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for FORE Biotherapeutics
